Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo

被引:16
|
作者
Zhou, Dawei [1 ]
Hayashi, Tsuyoshi [2 ,6 ]
Jean, Maxime [2 ]
Kong, Weili [1 ,7 ]
Fiches, Guillaume [1 ]
Biswas, Ayan [1 ]
Liu, Shuai [3 ]
Yosief, Hailemichael O. [3 ]
Zhang, Xiaofeng [3 ]
Bradner, Jay [4 ]
Qi, Jun [5 ]
Zhang, Wei [3 ]
Santoso, Netty [1 ]
Zhu, Jian [1 ]
机构
[1] Ohio State Univ, Dept Pathol, Coll Med, Columbus, OH 43210 USA
[2] Univ Rochester, Dept Microbiol & Immunol, Sch Med & Dent, Rochester, NY 14642 USA
[3] Univ Massachusetts, Chem Dept, Coll Sci & Math, Boston, MA 02125 USA
[4] Novartis Inst BioMed Res, Cambridge, MA 02139 USA
[5] Harvard Med Sch, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA
[6] Natl Inst Infect Dis, Tokyo 1628640, Japan
[7] Gladstone Inst, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA
来源
SCIENCE ADVANCES | 2020年 / 6卷 / 29期
关键词
PHYSICAL INTERACTION; LATENT RESERVOIR; SURVIVAL; REACTIVATION; ACTIVATION; RESISTANCE; APOPTOSIS; TARGETS; AURORA; DEATH;
D O I
10.1126/sciadv.aba1941
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although combination antiretroviral therapy is effective in controlling HIV-1 infection, latent HIV-1 proviruses cannot be eliminated. HIV-1 reactivation induced by the mere use of latency-reversing agents is insufficient to render death of reservoir cells, indicating that certain intrinsic survival mechanisms exist. We report that Polo-like kinase 1 (PLK1) plays a critical role in survival of CD4(+ )T cells that undergo HIV-1 reactivation from latency or de novo infection. PLK1 is elevated in both scenarios, which requires HIV-1 Nef. HIV-1 enhances PLK1 SUMOylation, causing its nuclear translocation and protein stabilization. Inhibition or knockdown of PLK1 markedly facilitates death of HIV-1-infected CD4(+) T cells. Furthermore, PLK1 inhibitors strikingly reduce the size of HIV-1 latent reservoirs in primary CD4(+) T cells. Our findings demonstrate that HIV-1 infection hijacks PLK1 to prevent cell death induced by viral cytopathic effects, and that PLK1 is a promising target for chemical "killing" of HIV-1 reservoir cells.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] TARGETING POLO-LIKE KINASE 1 (PLK1) FOR TREATMENT OF PEDIATRIC BRAIN CANCERS
    Lee, Cathy Y.
    Fotovati, Abbas
    Dunn, Sandra E.
    NEURO-ONCOLOGY, 2010, 12 : 11 - 11
  • [22] Impact of freezing Plk1 (polo-like kinase 1) by SBE13
    Keppner, S.
    Proschak, E.
    Schneider, G.
    Spaenkuch, B.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 383 : 72 - 72
  • [23] Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)
    Liu-Sullivan, Nancy
    Zhang, Jianping
    Bakleh, Amy
    Marchica, John
    Li, Jinyu
    Siolas, Despina
    Laquerre, Sylvie
    Degenhardt, Yan Y.
    Wooster, Richard
    Chang, Kenneth
    Hannon, Gregory F.
    Powers, Scott
    ONCOTARGET, 2011, 2 (12) : 1 - 11
  • [24] Polo-Like Kinase 1 (PLK1) Inhibition Decreases Mutational Activity in Bronchial Epithelial Cells Exposed to Tobacco Carcinogens
    Merrick, Daniel
    Donald, Elizabeth
    Malloy, Jessica
    Astling, David
    Franklin, Wilbur
    Aisner, Dara
    Crooks, Kristy
    Seager, Michael
    Haney, Jerry
    Keith, Robert
    Dwyer-Nield, Lori
    Tennis, Meredith
    Jones, Kenneth
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S539 - S540
  • [25] Structure based drug design and optimization of inhibitors of Polo-like Kinase 1 (PLK1)
    McBride, Christopher M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [26] Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma
    Cheng, Mao-Wei
    Wang, Bing-Chan
    Weng, Zhi-Qiang
    Zhu, Xiao-Wei
    ACTA HISTOCHEMICA, 2012, 114 (05) : 503 - 509
  • [27] Polo-like kinase 1 (Plk1) is a positive regulator of DNA replication in theXenopus in vitrosystem
    Ciardo, Diletta
    Haccard, Olivier
    Narassimprakash, Hemalatha
    Chiodelli, Virginie
    Goldar, Arach
    Marheineke, Kathrin
    CELL CYCLE, 2020, 19 (14) : 1817 - 1832
  • [28] Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
    Li, Shanshan
    Zhang, Yingjie
    Xu, Wenfang
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2013, 13 (14) : 2014 - 2025
  • [29] Mechanisms of mammalian polo-like kinase 1 (Plk1) localization: Self-priming
    Lee, Kyung S.
    Park, Jung-Eun
    Kang, Young H.
    Zimmerman, Wendy
    Soung, Nak-Kyun
    Seong, Yeon-Sun
    Kwak, Sahng-June
    Erikson, Raymond L.
    CELL CYCLE, 2008, 7 (02) : 141 - 145
  • [30] p53-dependent repression of polo-like kinase-1 (PLK1)
    McKenzie, Lynsey
    King, Sharon
    Marcar, Lynnette
    Nicol, Sam
    Dias, Sylvia S.
    Schumm, Katie
    Robertson, Pamela
    Bourdon, Jean-Christophe
    Perkins, Neil
    Fuller-Pace, Frances
    Meek, David W.
    CELL CYCLE, 2010, 9 (20) : 4200 - 4212